false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Four Pillars in the Management of Glomerular Disea ...
Four Pillars in the Management of Glomerular Diseases
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The talk argues that treatment of glomerular disease is shifting from merely delaying progression toward achieving remission—preserving kidney function, slowing eGFR decline to near normal aging, and reducing albuminuria. This often requires combining disease-specific immunotherapy with complementary, non-immunosuppressive treatments.<br /><br />The proposed four pillars are: lifestyle and blood-pressure management; targeted immunotherapy; endothelin receptor antagonists; SGLT2 inhibitors; non-steroidal mineralocorticoid receptor antagonists; and GLP-1 receptor agonists. Evidence from trials supports benefits such as reduced albuminuria and slower kidney-function decline, particularly for endothelin antagonists in IgA nephropathy and FSGS, SGLT2 inhibitors across diabetic and non-diabetic CKD, and finerenone in CKD, including glomerular-disease subgroups. GLP-1 agonists also show kidney and cardiovascular benefits, though dedicated glomerular-disease outcome trials are needed.<br /><br />Because direct evidence for many drug combinations remains limited, the speaker recommends considering early combination therapy by extrapolating from complementary mechanisms and studies in diabetic kidney disease, while acknowledging access and implementation barriers. The central message is to maximize foundational care and use multiple therapies where appropriate to reduce both kidney and cardiovascular risk.
Asset Caption
Yelena Drexler, MD, MS, FASN
Meta Tag
Speaker
Yelena Drexler
Keywords
glomerular disease
remission
albuminuria
immunotherapy
SGLT2 inhibitors
endothelin receptor antagonists
finerenone
×
Please select your language
1
English